<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This open study was designed to assess efficacy and safety of long-term therapy with cerebrolysin in 48 patients aged 59-77 years with mild and moderately severe vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The slowdown in the progress of this condition during the 3-year treatment period was evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy and safety of the drug was assessed clinically and with the use of standard scales and neuropsychological tests </plain></SENT>
<SENT sid="3" pm="."><plain>The long-term therapy with cerebrolysin was shown to be safe and highly efficacious as indicated by the improvement of cognitive and motor functions both at early and late stages of the treatment regardless of the severity of the disease </plain></SENT>
<SENT sid="4" pm="."><plain>It is concluded that long-term therapy with cerebrolysin slows down the progress of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and prevent deterioration of cognitive abilities </plain></SENT>
</text></document>